1. MOA (Mechanism of Action)

Tripeptide-2 is a synthetic biomimetic peptide specifically designed to target and improve the appearance of under-eye bags and facial puffiness through a targeted physiological approach.

Inhibition of TGF-β1 Signaling: The primary mechanism of Tripeptide-2 involves the modulation of the Transforming Growth Factor-beta 1 (TGF-β1) pathway. By partially inhibiting this pathway, it helps to:

• Reduce the abnormal differentiation of fibroblasts into adipocytes (fat cells) in the subdermal layer.
• Decrease the excessive deposition of extracellular matrix components that contribute to tissue volume and puffiness.

Improvement of Lymphatic Drainage: Tripeptide-2 is believed to support the natural lymphatic drainage system, helping to clear accumulated fluids and metabolic waste that can contribute to swelling, particularly in the delicate periorbital area.

Firming and Toning: By addressing the underlying structural causes of puffiness, it promotes a firmer, tighter, and more contoured appearance of the skin.

2. In Vitro Efficacy Data

Inhibition of Adipogenesis: In vitro studies on human fibroblasts demonstrated that Tripeptide-2 can significantly reduce the differentiation of fibroblasts into adipocytes by up to 40% under pro-adipogenic conditions, as measured by lipid droplet formation.

Reduction of Fibrotic Markers: The peptide was shown to downregulate the expression of key markers associated with fibrosis and excessive matrix deposition.

3. Clinical Results

Clinical studies on human volunteers confirm the efficacy of Tripeptide-2 in reducing the appearance of under-eye bags and improving overall facial contour.

• Reduction in Under-Eye Puffiness: In a 56-day clinical study, a formulation containing 5 ppm Tripeptide-2 applied twice daily resulted in a visible reduction in under-eye bag volume and severity in over 80% of participants.
• Improved Eyelid Contour: Photographic analysis showed a significant improvement in the smoothness and tightness of the eyelid contour, giving the eyes a more alert and rested appearance.
• Consumer Perception: A significant majority of participants self-reported a noticeable decrease in the appearance of puffiness and a more youthful look to their eye area.

Recommended Usage Level: 5 - 10 ppm (0.0005% - 0.001%). Effective at very low concentrations.

Suitable Formulations: Designed for targeted eye treatments and puffiness-prone areas.

• Eye Serums, Gels, and Creams
• Contouring and Lifting Serums
• Targeted Ampoules for Under-Eye Bags
• Sheet Masks for the Eye Area